272 related articles for article (PubMed ID: 12860932)
1. Interleukin 1alpha promotes Th1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB/c mice.
Von Stebut E; Ehrchen JM; Belkaid Y; Kostka SL; Molle K; Knop J; Sunderkotter C; Udey MC
J Exp Med; 2003 Jul; 198(2):191-9. PubMed ID: 12860932
[TBL] [Abstract][Full Text] [Related]
2. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice.
Biedermann T; Zimmermann S; Himmelrich H; Gumy A; Egeter O; Sakrauski AK; Seegmüller I; Voigt H; Launois P; Levine AD; Wagner H; Heeg K; Louis JA; Röcken M
Nat Immunol; 2001 Nov; 2(11):1054-60. PubMed ID: 11600887
[TBL] [Abstract][Full Text] [Related]
3. Leishmania major-infected murine langerhans cell-like dendritic cells from susceptible mice release IL-12 after infection and vaccinate against experimental cutaneous Leishmaniasis.
von Stebut E; Belkaid Y; Nguyen BV; Cushing M; Sacks DL; Udey MC
Eur J Immunol; 2000 Dec; 30(12):3498-506. PubMed ID: 11093169
[TBL] [Abstract][Full Text] [Related]
4. Differential regulation of IL-9-expression after infection with Leishmania major in susceptible and resistant mice.
Gessner A; Blum H; Röllinghoff M
Immunobiology; 1993 Dec; 189(5):419-35. PubMed ID: 8125519
[TBL] [Abstract][Full Text] [Related]
5. Induction of a Th2 population from a polarized Leishmania-specific Th1 population by in vitro culture with IL-4.
Mocci S; Coffman RL
J Immunol; 1995 Apr; 154(8):3779-87. PubMed ID: 7706719
[TBL] [Abstract][Full Text] [Related]
6. IL-18 gene therapy develops Th1-type immune responses in Leishmania major-infected BALB/c mice: is the effect mediated by the CpG signaling TLR9?
Li Y; Ishii K; Hisaeda H; Hamano S; Zhang M; Nakanishi K; Yoshimoto T; Hemmi H; Takeda K; Akira S; Iwakura Y; Himeno K
Gene Ther; 2004 Jun; 11(11):941-8. PubMed ID: 14985787
[TBL] [Abstract][Full Text] [Related]
7. T helper 1 response against Leishmania major in pregnant C57BL/6 mice increases implantation failure and fetal resorptions. Correlation with increased IFN-gamma and TNF and reduced IL-10 production by placental cells.
Krishnan L; Guilbert LJ; Wegmann TG; Belosevic M; Mosmann TR
J Immunol; 1996 Jan; 156(2):653-62. PubMed ID: 8543817
[TBL] [Abstract][Full Text] [Related]
8. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response.
Mattner F; Magram J; Ferrante J; Launois P; Di Padova K; Behin R; Gately MK; Louis JA; Alber G
Eur J Immunol; 1996 Jul; 26(7):1553-9. PubMed ID: 8766560
[TBL] [Abstract][Full Text] [Related]
9. Distinct roles for IL-1 receptor type I signaling in early versus established Leishmania major infections.
Kostka SL; Knop J; Konur A; Udey MC; von Stebut E
J Invest Dermatol; 2006 Jul; 126(7):1582-9. PubMed ID: 16645594
[TBL] [Abstract][Full Text] [Related]
10. Early IL-4 production does not predict susceptibility to Leishmania major.
Scott P; Eaton A; Gause WC; di Zhou X; Hondowicz B
Exp Parasitol; 1996 Nov; 84(2):178-87. PubMed ID: 8932767
[TBL] [Abstract][Full Text] [Related]
11. Pregnancy impairs resistance of C57BL/6 mice to Leishmania major infection and causes decreased antigen-specific IFN-gamma response and increased production of T helper 2 cytokines.
Krishnan L; Guilbert LJ; Russell AS; Wegmann TG; Mosmann TR; Belosevic M
J Immunol; 1996 Jan; 156(2):644-52. PubMed ID: 8543816
[TBL] [Abstract][Full Text] [Related]
12. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis.
Scott P
J Immunol; 1991 Nov; 147(9):3149-55. PubMed ID: 1833466
[TBL] [Abstract][Full Text] [Related]
13. Skin-derived macrophages from Leishmania major-susceptible mice exhibit interleukin-12- and interferon-gamma-independent nitric oxide production and parasite killing after treatment with immunostimulatory DNA.
von Stebut E; Belkaid Y; Nguyen B; Wilson M; Sacks DL; Udey MC
J Invest Dermatol; 2002 Sep; 119(3):621-8. PubMed ID: 12230504
[TBL] [Abstract][Full Text] [Related]
14. Dissociation of disease susceptibility, inflammation and cytokine profile in lmr1/2 congenic mice infected with Leishmania major.
Elso C; Kumar B; Smyth G; Foote S; Handman E
Genes Immun; 2004 May; 5(3):188-96. PubMed ID: 14762398
[TBL] [Abstract][Full Text] [Related]
15. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.
Skeiky YA; Kennedy M; Kaufman D; Borges MM; Guderian JA; Scholler JK; Ovendale PJ; Picha KS; Morrissey PJ; Grabstein KH; Campos-Neto A; Reed SG
J Immunol; 1998 Dec; 161(11):6171-9. PubMed ID: 9834103
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
[TBL] [Abstract][Full Text] [Related]
17. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis.
Scharton-Kersten T; Afonso LC; Wysocka M; Trinchieri G; Scott P
J Immunol; 1995 May; 154(10):5320-30. PubMed ID: 7730635
[TBL] [Abstract][Full Text] [Related]
18. Leishmania major: a clone with low virulence for BALB/c mice elicits a Th1 type response and protects against infection with a highly virulent clone.
Li J; Nolan TJ; Farrell JP
Exp Parasitol; 1997 Sep; 87(1):47-57. PubMed ID: 9287957
[TBL] [Abstract][Full Text] [Related]
19. c-Rel promotes type 1 and type 17 immune responses during Leishmania major infection.
Reinhard K; Huber M; Wostl C; Hellhund A; Toboldt A; Abass E; Casper B; Joeris T; Herr C; Bals R; Steinhoff U; Lohoff M; Visekruna A
Eur J Immunol; 2011 May; 41(5):1388-98. PubMed ID: 21469108
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell-derived IL-12p40 homodimer contributes to susceptibility in cutaneous leishmaniasis in BALB/c mice.
Nigg AP; Zahn S; Rückerl D; Hölscher C; Yoshimoto T; Ehrchen JM; Wölbing F; Udey MC; von Stebut E
J Immunol; 2007 Jun; 178(11):7251-8. PubMed ID: 17513774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
